Biotech | February 24, 2022
Aadi Bioscience launches Fyarro in the USA
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Fyarro added to NCCN guidelines as the only preferred mTOR inhibitor to treat malignant PEComa
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
Robust pipeline with around 50 projects in clinical development / cardiology portfolio poised for growth with launch products Kerendia (finerenone) and Verquvo (vericiguat)
he financing was significantly oversubscribed with high demand from both existing and new investors.
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
He will be responsible for developing the company's pipeline of partnered and in-house discovery programs,
Prior to joining Biosion, Edwards was Vice President of Corporate Strategy and operations at Ionis Pharmaceuticals.
The facility will manufacture its Herceptin biosimilar, Tuznue
The sale is expected to close in the first quarter of 2022
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
Subscribe To Our Newsletter & Stay Updated
